期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 163, 期 3, 页码 393-399出版社
WILEY
DOI: 10.1111/bjh.12541
关键词
immune haemolytic anaemia; clinical trials; antibody therapy
类别
资金
- Roche A/S, Denmark
The impact of first-line treatment with the anti-CD 20 chimeric monoclonal antibody rituximab in patients with warm-antibody reactive autoimmune haemolytic anaemia (WAIHA) is unknown. We report the first randomized study of 64 patients with newly diagnosed WAIHA who received prednisolone and rituximab combined (N=32) or prednisolone monotherapy (N=32). After 12months, a satisfactory response was observed in 75% of the patients treated with rituximab and prednisolone but in a significantly smaller proportion (36%) of those given prednisolone alone (P=0 center dot 003). Furthermore, relapse-free survival was significantly better after the combined therapy than after prednisolone monotherapy (P=0 center dot 02). After 36 months, about 70% of the patients were still in remission in the rituximab-prednisolone group, whereas only about 45% were still in complete or partial remission in the prednisolone group. There was no significant difference between the two groups regarding adverse reactions to the studied medications. Likewise, serious adverse events were equally distributed, and no allergic reactions to rituximab were recorded. In conclusion, our data show that using rituximab and prednisolone combined rather than prednisolone alone as first-line treatment in WAIHA increases both the rate and the duration of the response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据